1. Home
  2. PHAR vs FLGT Comparison

PHAR vs FLGT Comparison

Compare PHAR & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

N/A

Current Price

$17.10

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Logo Fulgent Genetics Inc.

FLGT

Fulgent Genetics Inc.

HOLD

Current Price

$23.60

Market Cap

867.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHAR
FLGT
Founded
1988
2011
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
867.4M
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
PHAR
FLGT
Price
$17.10
$23.60
Analyst Decision
Strong Buy
Buy
Analyst Count
2
3
Target Price
$38.00
$28.33
AVG Volume (30 Days)
32.4K
175.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$18,730,000.00
Revenue This Year
$27.75
$16.84
Revenue Next Year
$9.39
$9.74
P/E Ratio
$3,041.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.50
$14.57
52 Week High
$21.34
$31.04

Technical Indicators

Market Signals
Indicator
PHAR
FLGT
Relative Strength Index (RSI) 48.93 34.67
Support Level $16.35 $21.97
Resistance Level $17.08 $23.70
Average True Range (ATR) 0.57 0.77
MACD 0.06 0.04
Stochastic Oscillator 77.74 31.84

Price Performance

Historical Comparison
PHAR
FLGT

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About FLGT Fulgent Genetics Inc.

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Share on Social Networks: